U.S. drugmaker Merck & Co has joined the race to make a cut-price copy of Sanofi's top-selling insulin treatment Lantus, increasing the long-term threat to the French company's $7 billion-a-year product. Merck, which is working with Samsung Bioepis on the project, said on Monday its version of glargine - the generic name for Lantus - would soon enter late-stage Phase III studies in type 1 and type 2 diabetes. Until now, the only company with a copycat version of Lantus in late-stage clinical development has been Eli Lilly.
Help employers find you! Check out all the jobs and post your resume.
